Partner With Us NRI

Alembic Pharmaceuticals Ltd share Price Today

Company details

6M Return 29.66%
1Y Return 27.75%
Mkt Cap.(Cr) 15,060.66
Volume 69,521
Div Yield 1.03%
OI Chg %
Volume 69,521

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Muted numbers; Cautious outlook with overheads recalibration…
About The Stock

    Alembic Pharma operates in international generics (US:31% & ex-US: 15% in FY22), domestic branded (36% in FY22) and API (18% in FY22).

    • Domestic business has 1.5% of market share of IPM with three brands in the top 100. Going ahead, emphasis is on specialty segment with 94% of new launches being specialty products
    • The company has invested ~ ₹ 1800 crore in recent years in facilities geared mainly towards US formulations. As of FY22, it has filed 230 ANDA and has 160 approvals with 105 launches in the US

    Alembic reported traction in US, while profitability was affected due to non-recurring expenses at its subsidiary Aleor (now wholly owned)

    • Sales grew 10.6% YoY to ₹ 1415.7 crore, driven by 17.3% YoY growth in US generics to ₹ 557 crore
    • EBITDA was at ₹ 160.1 crore, down 50% YoY with margins at 11.3%. Adjusted EBITDA for Aleor’s impact was ₹ 286 crore with margins at 20%
    • PAT was at ₹ 35.5 crore (down 85.9% YoY). Adjusting for ₹ 145 crore impact of Aleor, adjusted PAT was at ₹ 180.5 crore

Click here for full recommendation

Research view on more stocks

Alembic Pharmaceuticals announced Q2FY24 & H1FY24 results:

1. Financial Highlights:
- Net Sales grew 8% to Rs 1,595 crore for Q2FY24.
- Net Profit for the quarter at Rs 137 crore.
- Net Sales grew 13% to Rs 3,081 crore for the H1FY24.
- Net Profit for H1FY24 at Rs 257 crore.

2. India Branded Business:
- India Branded Business at Rs 577 crore witnessed growth of 5% in Q2FY24 against IPM growth of 7%.
- Specialty therapies recorded growth of 10% vis a vis industry growth of 9%.
- Performed relatively better than the market in the Antibiotic and Respiratory segments.
- Animal Health business recorded growth of 32% over Q2FY23.

3. International Business:
- US Generics at Rs 444 crore up by 6% on a YoY basis and by 14% on a QoQ basis.
- Ex-US International Formulations grew 17% to Rs 252 crore in the quarter.
- Regular exports from both general injectable and oncology plants.

4. API Business:
- API business grew 10% at Rs 322 crore in the quarter.
- 132 cumulative DMF Filings.

Shaunak Amin, Managing Director, Alembic Pharmaceuticals, said, "Despite the challenges of a muted demand in the Antibiotic and respiratory market, it was a satisfactory quarter, backed with a strong performance by our specialty and animal healthcare portfolio. We are confident of returning to an industry-beating growth moving forward."

Pranav Amin, Managing Director, Alembic Pharmaceuticals, said, "It was a satisfactory quarter led by growth in all the verticals of the company, in particular Ex-US which grew by 17% and the API business outperformed with a 10% growth during the quarter."



Result PDF

View Other Company Results


Investment recommendation
Muted numbers; Cautious outlook with overheads recalibration…
Call Date
08 May 2023
Entry Price 555.00
Target Price 530.00
12 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Alembic Pharmaceuticals Ltd Stocks COMPARISION


Equity Capital: 4,370.47 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 19,382.05 39,977.50
LAST 3M 58,542.74 22,989.39
LAST 6M 99,640.08 94,952.32
LAST 12M 166,983.77 142,188.84
Alembic Pharmaceuticals Limited - Loss of Share Certificates

Dec 08, 2023 l NSE Announcement

Alembic Pharmaceuticals Limited - Change in Management

Dec 04, 2023 l NSE Announcement

Date Action Type Ratio
Jul 28, 2023 Dividend 400
Aug 17, 2022 Dividend 500
Jul 19, 2021 Dividend 700

Alembic Pharmaceuticals Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Alembic Pharmaceuticals Ltd., a pharmaceutical company engaged in manufacturing pharmaceutical products, substances, and intermediates, is recognised as a market leader in India for anti-infective drugs in the macrolides segment. The company was incorporated in 1907, with its headquarters in Vadodara. For FY 2021-2022, Alembic Pharmaceuticals Ltd. recorded a total revenue of Rs 5,356.25 crore, down 0.87% from the previous financial year, 2020-2021. On 10 October 2022, the company’s market capitalisation stood at Rs 12,014 crore.

    The company is listed on the Bombay Stock Exchange with the code 533573, and on the National Stock Exchange with the code APLLTD.

    Alembic Pharmaceuticals Ltd. manufactures and markets Indian formulations, international generics, and active pharmaceutical ingredients across the globe. During the quarter that ended in June 2022, the company reported a loss of Rs 65.88 crore after three consecutive quarters of profits.

    The company’s shareholding pattern at the end of the June 2022 quarter represented a promoter stake of 69.61%, a foreign institutional investor stake of 5.94%, a domestic institutional investor stake of 12.15%, and a public stake of 12.3%. The leading promoter was Nirayu Limited having a 35.63% stake. During the same quarter, the company’s mutual fund holdings decreased from 5.18% to 5.01%, and foreign institutional investor holdings also decreased from 6.02% to 5.94%.

    Mr Chirayu Amin is the company’s chairman and CEO. Mr Praniv Amin and Mr Shaunak Amin are the managing directors. The other members of the leadership team include Mr Raj Kumar Baheti, Mr Pranav Parikh, Mr K G Ramanathan, Mr Ashok Barat, Mr Paresh Saraiya, and Dr Archana Hingorani. The company’s auditors include K C Mehta & Co and K S Aiyar & Co. As of 30 June 2022, Alembic Pharmaceuticals Ltd.’s total outstanding shares were 19.66 crores.

    On 10 October 2022, Alembic Pharmaceuticals Ltd.’s share price closed at Rs 610.30 on BSE and at Rs 611.25 on NSE. The company’s 52-week high share price was Rs 864.05, and the 52-week low share price was Rs 577.75.

    As of September 2022, Union Liquid Fund had a 5.23% stake in Alembic Pharmaceuticals Ltd. The other mutual fund holdings include Kotak Small Cap Fund, DSP Midcap Fund, and DSP Healthcare Fund, with a 2.10%, 1.63%, and 1.39% stake, respectively.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Registered Address

Alembic Road, , Vadodara, Gujarat, 390003

Tel : 91-0265-2280550
Email : apl.investors:alembic.co.in
Website : http://www.alembicpharmaceuticals.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 533573
Book Closure Date (Month) :
BSE Group : A
ISIN : INE901L01018

FAQ’s on Alembic Pharmaceuticals Ltd Shares

You can buy Alembic Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Alembic Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 11, 2023 03:54 PM the closing price of Alembic Pharmaceuticals Ltd was ₹ 766.20.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 11, 2023 03:54 PM, the market cap of Alembic Pharmaceuticals Ltd stood at ₹ 15,060.66.

The latest PE ratio of Alembic Pharmaceuticals Ltd as of Dec 11, 2023 03:54 PM is 28.67

The latest PB ratio of Alembic Pharmaceuticals Ltd as of Dec 11, 2023 03:54 PM is 0.29

The 52-week high of Alembic Pharmaceuticals Ltd is ₹ 839.00 while the 52-week low is ₹ 462.30

According to analyst recommendations, Alembic Pharmaceuticals Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app